Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Actinogen Medical ( (AU:ACW) ) has shared an announcement.
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW, has applied for quotation of additional ordinary fully paid shares. The move marginally increases its listed equity base, reflecting the conversion or exercise of existing options or other convertible securities.
The company will have 67,499 new ordinary fully paid shares quoted on the ASX from 26 February 2026. While small in scale, the issuance formalises earlier commitments embedded in its capital structure and modestly expands the free float available to investors.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australian biotechnology company listed on the ASX under the ticker ACW. The company operates in the medical and life sciences sector, focusing on the development of therapies, though this announcement provides no further detail on its specific products or lead programs.
Average Trading Volume: 5,233,802
Technical Sentiment Signal: Hold
Current Market Cap: A$148.9M
For an in-depth examination of ACW stock, go to TipRanks’ Overview page.